Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure.
In an attempt to provide an objective means of comparing the anticoagulant action of heparin with those of newly developed low MW heparin-like anticoagulants we have utilized the fibrinpeptide A assay as a method of determining fibrin formation during haemodialysis. In vivo suppression of FPA levels by increasing doses of administered anticoagulant enables equivalent effective doses of anticoagulants to be determined without making prior assumptions about which ex vivo activities of these compounds are responsible. In this communication we summarize results of studies with heparin and three low MW heparin(oid)s.
Lane
D A
DA
Department of Haematology and Medicine, Charing Cross Hospital, Hammersmith, London, UK.
Ireland
H
H
Tew
C J
CJ
Flynn
A
A
Curtis
J R
JR
D001777:Blood Coagulation / Q000187:drug effects; D005344:Fibrinopeptide A / Q000378:metabolism; D006493:Heparin / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D006435:Renal Dialysis / Q000379:methods
D006495:Heparin, Low-Molecular-Weight; D005344:Fibrinopeptide A; D006493:Heparin